Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

$zyne $3.75

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Taurus69 Member Profile
Member Level 
Followed By 205
Posts 27,970
Boards Moderated 0
Alias Born 08/30/12
160x600 placeholder
Ladenburg Thalmann & Co. Keeps a Buy Rating on Zynerba Pharmaceuticals (ZYNE) TipRanks - 1/6/2022 7:45:14 AM
Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference GlobeNewswire Inc. - 1/6/2022 7:00:00 AM
Zynerba Pharmaceuticals (ZYNE) Gets a Hold Rating from Needham TipRanks - 1/5/2022 3:35:20 PM
Zynerba Pharmaceuticals (ZYNE) Gets a Buy Rating from H.C. Wainwright TipRanks - 1/5/2022 11:55:12 AM
Zynerba pushes back development of Zygel in a group of epilepsies Seeking Alpha - 1/4/2022 4:48:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2022 4:19:43 PM
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE GlobeNewswire Inc. - 1/4/2022 4:05:00 PM
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium GlobeNewswire Inc. - 12/6/2021 7:00:00 AM
Zynerba Pharma pops 4% after securing new European patent for Zygel CBD gel Seeking Alpha - 11/22/2021 8:03:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/22/2021 7:23:52 AM
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™ GlobeNewswire Inc. - 11/22/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 7:35:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/15/2021 7:24:52 AM
Zynerba Pharmaceuticals EPS misses by $0.01 Seeking Alpha - 11/15/2021 7:24:29 AM
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights GlobeNewswire Inc. - 11/15/2021 7:00:00 AM
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October GlobeNewswire Inc. - 10/21/2021 7:00:00 AM
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit GlobeNewswire Inc. - 10/19/2021 4:15:00 PM
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition GlobeNewswire Inc. - 10/8/2021 7:30:00 AM
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2021 7:13:01 AM
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome GlobeNewswire Inc. - 9/13/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2021 7:11:22 AM
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/7/2021 7:11:28 AM
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open GlobeNewswire Inc. - 9/7/2021 7:00:00 AM
Taurus69 Member Level  Monday, 08/03/20 03:30:06 AM
Re: None
Post # of 2660 
$zyne $3.75

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences